ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO829

Expert-Level Segmentation Using Deep Learning for the Volumetry of Polycystic Kidney and Liver

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic


  • Kim, Hyunsuk, Hallym University, Kidney Research Institute, Chuncheon, Korea (the Republic of)
  • Yoon, Jong-woo, Hallym University, Kidney Research Institute, Chuncheon, Korea (the Republic of)
  • Kim, Hyo Jin, Dongguk University College of Medicine, Gyeongju-si, Korea (the Republic of)
  • Han, Miyeun, Pusan National University Hospital, Busan, Korea (the Republic of)
  • Bae, Eunjin, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of)
  • Min, Hyun-seok, Tomocube, Seoul, Korea (the Republic of)
  • Choi, Gwangho, Hallym Chuncheon Sacred Heart Hospital, Chuncheon, Korea (the Republic of)
  • Lee, Joonghyup, Spectra, Seoul, Korea (the Republic of)
  • Choi, Jongsuk, Dongguk University, Seoul, Korea (the Republic of)
  • Cho, Hyungjoo, Tomocube, Seoul, Korea (the Republic of)
  • Koh, Junga, Gangneung Dongin Hospital, Gangneung-si, Korea (the Republic of)
  • Jung, Houn, Hallym University Medical Center, Chuncheon-si, Korea (the Republic of)
  • Shin, Tae young, Hallym Chuncheon Sacred Heart Hospital, Chuncheon, Korea (the Republic of)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with serious impacts on patients. In polycystic kidney and liver diseases (PKLD), including ADPKD, volumetry is used to assess disease progression and drug efficiency. However, since no rapid and accurate method has been developed, volumetry has not been established in clinical practice, hindering the development of therapies for this disease. This study presents an AI-based PKLD volumetry method that showed powerful performance.


As a first experiment, the performance of AI was evaluated compared to ground-truth (GT). We trained a V-net based convolutional neural network on 175 ADPKD computed tomography (CT) segmentations (GT) produced by 3 experts using images from 214 patients. The Dice similarity coefficient (DSC), inter-observer correlation coefficient (ICC), and Bland-Altman plots of 39 GT and AI segmentations in the validation set were compared. Next, the performance of AI on the segmentation of 50 random CT images was compared to that of 11 PKLD specialists based on the resulting DSC and ICC.


The DSC and ICC of the AI were 0.961 and 0.999729, respectively. The error rate was within 3% for approximately 95% of CT scans (error <1%, 46.2%, 1% ≤ error <3%, 48.9%). Compared to the specialists, AI showed moderate performance. Furthermore, an outlier in our results confirmed that even PKLD specialists can make mistakes in volumetry.


PKLD volumetry using AI was fast and accurate. AI showed comparable performance to that of human specialists, suggesting its practical use in clinical settings.


  • Other NIH Support